Cytokine-modified tumor vaccines: An antitumor strategy revisited in the age of molecular medicine

Cancer Nursing

Volumn 21, Issue 3, 1998, Pages 167-177

  Weber, Christine E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Active immunotherapy; Delayed type hypersensitivity skin testing; Gene therapy; Tumor immunology; Tumor vaccines

Indexed keywords

CYTOKINE; EMLA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ANALGESIA; AUTOIMMUNITY; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; GENE TARGETING; GENE THERAPY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; NURSING; PRIORITY JOURNAL; REVIEW; SKIN TEST; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR IMMUNOLOGY; VACCINATION; VACCINE PRODUCTION; VITILIGO;

CANCER VACCINES; CYTOKINES; GENE THERAPY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; NEOPLASMS; ONCOLOGIC NURSING; SKIN TESTS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0031805433     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-199806000-00003     Document Type: Review

References (58)

1. Livingston PO. Active specific immunotherapy in the treatment of patients with cancer. In: Oettgen HF, ed. Immunology and Allergy-Clinics of North America: Human cancer immunology II. Philadelphia: WB Saunders, 1991:401-23.
2. Mullis KB. The unusual origin of the polymerase chain reaction. Sci Am 1990;262:56-61, 64-5.
3. Loescher LJ. Genetics in cancer prediction, screening and counseling, Part I. Oncol Nurs Forum 1995;22:10-15.
4. Dranoff G, Jaffee E, Lazenby A, et al. Irradiated tumor cells secreting murine GM-CSF are unique in their ability to stimulate potent anti-tumor immunity in a non-immmunogenic tumor model. Proc Natl Acad Sci 1993;90:3539-43.
5. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene modified tumor cells. Hum Gene Ther 1994;5:153-64.
6. Gilboa E, Lyerly HK, Vieweg J, Saito S. Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol 1994;5:409-17.
7. Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 1994;6:96-105.
8. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and clinical gene therapy. Eur J Immunol 1995;25:1137-40.
9. Urban JL, Schreiber H. Tumor antigens. Ann Rev Immunol 1992;10:617-44.
10. Sanda M, Ayyagari S, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151:622-6.
11. Hoover HC, Surdyke MG, Dangel RB, et al. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res 1984;44:1671.
12. Abrahms RA, Grochow, LB. Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head. Surg Clin North Am 1995;75:925-37.
13. Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci 1982;79:4718-22.
14. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Sem Oncol 1996;23:88-100.
15. Nossal GJ. Tolerance and ways to break it. Ann NY Acad Sci 1993;690:34-9.
16. Behringwerke AG. Vaccination for treatment of tumors: A critical comment. Crit Rev Oncog 1994;5:555-87.
17. Zier KS, Gansbacher B. The impact of gene therapy on T-cell function in cancer. Hum Gene Ther 1995;6:1259-64.
18. Vile RG. Tumor-specific gene expression. Sem Cancer Biol 1994;5:429-36.
19. Salmons B, Guenzburg WH. Targeting of retroviral vectors for gene therapy. Hum Gene Ther 1993;4:129-41.
20. Vieweg J, Gilboa E. Considerations for the use of cytokjne-secreting tumor cell preparations for cancer treatment. Cancer Invest 1995;13:193-201.
21. Moolten FL, Cupples LA. A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum Gene Ther 1992;3: 479-86.
22. Boris-Laune K, Temin HM. The retroviral vector: Replication cycle and safety considerations for retrovirus mediated gene therapy. Ann NY Acad Sci 1993;716:59-70.
23. Porgador A, Feldman M, Eisenbach, L. Immunotherapy of tumor metastasis via gene therapy. Nat Immun 1994;13:113-30.
24. Mastrangelo MJ, Berd D, Nathan FE, Lattime EC. Gene therapy for human cancer: An essay for clinicians. Semin Oncol 1996;23:4-21.
25. Rosenthal FM, Zier KS, Gansbacher B. Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility eenes to enhance immunogenicity. Curr Opin Oncol 1994;6: 611-15.
26. Foa R, Guarini A, Gignetti A, Cronin K, Rosenthal F, Gansbacher B. Cytokine gene therapy: A new strategy for the management of cancer patients. Nat Immun 1994;13:65-75.
27. Rosenberg, SA. Secrecy in medical research. N Engl J Med 1996;334:392-4.
28. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 1996;23:101-7.
29. Inaba K, Inama M, Steinman, RM, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte-macrophage-colony-stimulating-factor. J Exp Med 1992;176:1693-702.
30. Howard MC, Miyajima A, Coffman R. T-cell-derived cytokines and their receptors. In: Paul WE, ed. Fundamental immunology, 3rd ed. New York: Raven Press, 1993:772-4.
31. Lucy DR, Nicholson-Weller A, Weller P. Mature human eosinophils have the capacity to express HLA-DR. Proc Nat Acad Sci USA 1989;86:1348-51.
32. Pardoll DM. Strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 1993;5:719-25.
33. Gerner RF, Moore GE. Feasibility study of active immunotherapy in patients with solid tumors. Cancer 1996;38:131-43.
34. Sutherland DC, Wilson JD. Skin testing in the assessment of cell-mediated immunity. New Zeal Med J 1977;85:41-5.
35. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975;293:501-2.
36. Stiles DP. Clinical laboratory methods for detection of cellular immunity. In: Stites DP, Terr AI, eds. Basic and clinical immunology, 7th ed. Norwalk, CT: Appleton & Lange, 1991:263-5.
37. McCune GS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990;3:62-6.
38. Cotran RS, Kumar V, Robbins SL. Diseases of immunity in pathologic basis of disease, 4th ed., Chapter 5. Philadelphia: WB Saunders, 1989
39. Eilber FR, Morton DL. Impaired immunologie reactivity and recurrence following cancer surgery. Cancer 1970;25:362-7.
40. Fass L, Herberman RB, Ziegler J, Kiryabwire JW. Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells. Lancet 1970;282:776-9.
41. Berd D, Maguire HC, Mastrangelo MJ. Induction of cell mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986;46:2572-7.
42. Oren ME, Herberman RB. Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells. Clin Exp Immunol 1971;9:45-56.
43. Moesgaard F, Lykkegaard Nielsen M, Larsen PN, Christophersen S, Mosbech H. Cell-mediated immunity assessed by skin testing. Allergy 1988;43:109-12.
44. Vinson WM. Anergy and delayed hypersensitivity skin testing. Am Fam Physician 1983;27:143-7.
45. Burdick JF, Wells SA, Herberman RB. Immunologie evaluation of patients with cancer by delayed hypersensitivity reactions. Surg Gyneco Obstet 1975;141:779-91.
46. Oldham RK, Weiner RS, Mathe, G, Herberman RB. Cell-mediated immune responsiveness of patients with acute lymphocytic leukemia in remission. Im J Cancer 1976;17:326-37.
47. Hammer JH, Nielsen HJ, Moesgaard F, et al. Duration of postoperative immunosuppression assessed by repeated delayed type hypersensitivity skin tests. Eur Surg Res 1992;24:133-7.
48. Keystone EG, Demerieux P, Gladman D, Poplonski L, Piper S, Buchanan R. Enhanced delayed hypersensitivity skin test reactivity with serial testing in healthy volunteers. Clin Exp Immunol 1980;40:202-5.
49. Rankin E. Scientific aspects of gene therapy in melanoma. Curr Opin Oncol 1995;7:192-6.
50. Livingstone P. Conference overview. Ann NY Acad Sci 1993;690:1-5.
51. Talal N. Lessons from autoimmunity. Ann NY Acad Sci 1993;690:19-23.
52. Houghton AH, Setaluri V, Brigitte B, et al. Recognition of autoantigens by patients with melanoma. Ann NY Acad Sci 1993;690:59-65.
53. Ledley FD, Brody B, Kozinetz CA, Mize, SG. The challenge of follow-up for clinical trials of somatic gene therapy. Hum Gene Ther 1992;3:657-63.
54. Kedar E, Klein E. Cancer immunotherapy: Are the results discouraging? Can they be improved? Adv Immmunol 1995;58:245-322.
55. Fidler IF, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Prog Surg 1987;24:137-209.
56. Skolnick AA. Essential components now in place for clinical testing of cancer vaccine strategies, experts say. JAMA 1995;273: 528-30.
57. Henderson RA, Finn OJ. Human tumor antigens are ready to fly. Adv Immunol 1996;162:217-49.
58. Schirrmacher V. Tumor vaccine design: Concepts, mechanisms, and efficacy testing. Int Arch Allergy Imunol 1995;108:340-4.